Should I buy or sell Avidity Biosciences stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RNA shares. View RNA analyst ratings or view top-rated stocks .

What is Avidity Biosciences' stock price target for 2024?

6 Wall Street research analysts have issued 1 year target prices for Avidity Biosciences' shares. Their RNA share price targets range from $20.00 to $60.00. On average, they predict the company's stock price to reach $36.33 in the next twelve months. This suggests a possible upside of 57.8% from the stock's current price. View analysts price targets for RNA or view top-rated stocks among Wall Street analysts .

How have RNA shares performed in 2024?

Avidity Biosciences' stock was trading at $9.05 at the start of the year. Since then, RNA stock has increased by 154.5% and is now trading at $23.03. View the best growth stocks for 2024 here .

When is Avidity Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RNA earnings forecast .

How were Avidity Biosciences' earnings last quarter?

Avidity Biosciences, Inc. (NASDAQ:RNA) released its quarterly earnings data on Wednesday, February, 28th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.25. The biotechnology company had revenue of $2.19 million for the quarter, compared to the consensus estimate of $32.08 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 39.74% and a negative net margin of 2,219.87%.

What ETFs hold Avidity Biosciences' stock?

ETFs with the largest weight of Avidity Biosciences (NASDAQ:RNA) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON) , Morningstar US Small Growth (MSGR) , Simplify Propel Opportunities ETF (SURI) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) , ALPS Medical Breakthroughs ETF (SBIO) and Harbor Disruptive Innovation ETF (INNO) . iShares Micro-Cap ETF (IWC) .

What other stocks do shareholders of Avidity Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI) , Inovio Pharmaceuticals (INO) , Novavax (NVAX) , Sarepta Therapeutics (SRPT) , Avid Bioservices (CDMO) , Dynavax Technologies (DVAX) , iBio (IBIO) , Intel (INTC) , Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT) .

When did Avidity Biosciences IPO?

Avidity Biosciences (RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.

Who are Avidity Biosciences' major shareholders?

Avidity Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.07%) and Mirador Capital Partners LP (0.06%). Insiders that own company stock include Arthur A Levin , Michael F Maclean, Rtw Investments, Lp, Sarah Boyce and W Michael Flanagan. View institutional ownership trends .

How do I buy shares of Avidity Biosciences?

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RNA

Avidity Biosciences (RNA) Stock Price, News & Analysis

→ Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad)

Free RNA Stock Alerts

$23.03

-0.52 (-2.21%)

(As of 02:40 PM ET)

Compare

Today's Range: $22.78
▼
$23.98
50-Day Range: $12.51
▼
$26.87
52-Week Range: $4.82
▼
$27.66

Volume: 605,051 shs
Average Volume: 1.18 million shs
Market Capitalization: $1.84 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.33

Get Avidity Biosciences alerts:

Avidity Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 57.8% Upside
$36.33 Price Target
Short Interest: Bearish
12.52% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.66
Based on 4 Articles This Week
Insider Trading: Selling Shares
$4.69 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.07) to ($3.79) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.97 out of 5 stars

Medical Sector

802nd out of 914 stocks

Pharmaceutical Preparations Industry

362nd out of 415 stocks

3.5

Analyst's Opinion

Consensus Rating
Avidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Avidity Biosciences has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
12.52% of the outstanding shares of Avidity Biosciences have been sold short.
Short Interest Ratio / Days to Cover
Avidity Biosciences has a short interest ratio ("days to cover") of 8.2.
Change versus previous month
Short interest in Avidity Biosciences has recently increased by 15.78%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Avidity Biosciences does not currently pay a dividend.
Dividend Growth
Avidity Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RNA.

2.6

News and Social Media Coverage

News Sentiment
Avidity Biosciences has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Avidity Biosciences this week, compared to 3 articles on an average week.
Search Interest
Only 9 people have searched for RNA on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,690,942.00 in company stock.
Percentage Held by Insiders
Only 2.00% of the stock of Avidity Biosciences is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Avidity Biosciences are expected to decrease in the coming year, from ($3.07) to ($3.79) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Avidity Biosciences is -7.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Avidity Biosciences is -7.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Avidity Biosciences has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Avidity Biosciences Stock (NASDAQ:RNA)

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

RNA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RNA Stock News Headlines

April 5, 2024 | insidertrades.com

Arthur A. Levin Sells 20,000 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) Stock

April 13, 2024 | msn.com

Unveiling the key role of RNA modification in HIV-1 survival and replication

April 18, 2024 | The Freeport Society (Ad)

Next President (Not Trump. Not Biden.)

Do you want to see who I believe will be the next president of the U.S.A? It won't be Biden… And it won't be Trump.

April 13, 2024 | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Rating Reiterated by Needham & Company LLC

April 11, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Carisma Therapeutics (CARM), Avidity Biosciences (RNA) and Vera Therapeutics (VERA)

April 4, 2024 | finance.yahoo.com

Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares

March 27, 2024 | prnewswire.com

Avidity Biosciences to Participate in Upcoming Investor Conferences

March 17, 2024 | finance.yahoo.com

RNA Apr 2024 17.500 call

April 18, 2024 | The Freeport Society (Ad)

Next President (Not Trump. Not Biden.)

Do you want to see who I believe will be the next president of the U.S.A? It won't be Biden… And it won't be Trump.

March 16, 2024 | finance.yahoo.com

RNA Apr 2024 17.500 put

March 16, 2024 | finance.yahoo.com

RNA Apr 2024 22.500 call

March 15, 2024 | finance.yahoo.com

Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)

March 7, 2024 | markets.businessinsider.com

Avidity Biosciences: Strong Buy Rating Amidst Positive Clinical Developments and Price Target Surge

March 5, 2024 | seekingalpha.com

Avidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Data

March 5, 2024 | markets.businessinsider.com

A Closer Look at 5 Analyst Recommendations For Avidity Biosciences

March 5, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Avidity Biosciences Following Promising MARINA-OLE Study Data and RNA Analysis

March 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Avidity Biosciences’s Promising MARINA-OLE Trial Data Indicates Significant DM1 Treatment Breakthrough

March 4, 2024 | msn.com

Avidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular Disease

March 4, 2024 | markets.businessinsider.com

Avidity Accelerates Phase 3 HARBOR Study Initiation To Q2 - Quick Facts

March 4, 2024 | finance.yahoo.com

Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial

March 4, 2024 | finance.yahoo.com

Top 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular Dystrophy

March 2, 2024 | investing.com

Avidity Biosciences secures $400 million in private placement

March 1, 2024 | finance.yahoo.com

Avidity Biosciences Full Year 2023 Earnings: Misses Expectations

February 29, 2024 | edition.cnn.com

Avidity Biosciences Inc

February 29, 2024 | seekingalpha.com

Avidity Biosciences: DMD Advancement And 2024 Catalysts Make It A Must-Watch

February 29, 2024 | prnewswire.com

Avidity Biosciences Honors Rare Disease Day®

February 29, 2024 | finanznachrichten.de

Avidity Biosciences, Inc.: Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights

See More Headlines

Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RNA
CUSIP: N/A
CIK: 1574111
Web: www.aviditybiosciences.com
Phone: 858-401-7900
Fax: N/A
Employees: 253
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $36.33
High Stock Price Target: $60.00
Low Stock Price Target: $20.00
Potential Upside/Downside: +54.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-212,220,000.00
Net Margins: -2,219.87%
Pretax Margin: -2,219.87%
Return on Equity: -39.74%
Return on Assets: -34.98%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.58
Quick Ratio: 7.58

Sales & Book Value

Annual Sales: $9.56 million
Price / Sales: 196.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.76 per share
Price / Book: 3.48

Miscellaneous

Outstanding Shares: 79,720,000
Free Float: 78,125,000
Market Cap: $1.88 billion
Optionable: Optionable
Beta: 0.78

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Dr. Troy Edward Wilson J.D. (Age 55)
Ph.D., Co-Founder & Chairman
Comp: $67.5k
Ms. Sarah Boyce (Age 52)
President, CEO & Director
Comp: $1.05M
Mr. Michael F. MacLean (Age 58)
Chief Financial & Chief Business Officer
Comp: $701.64k
Dr. W. Michael Flanagan Ph.D. (Age 62)
Chief Scientific & Technical Officer
Comp: $678.74k
Ms. Teresa McCarthy (Age 60)
Chief Human Resources Officer
Comp: $665.14k
Mr. Eric B. Mosbrooker (Age 56)
Chief Strategy Officer
Comp: $42.5k
Prof. Mark E. Davis
Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers
Dr. Frank P. McCormick Ph.D. (Age 74)
Scientific Founder & Member of Scientific Advisory Board
Mr. Geoffrey M. Grande C.F.A.
VP of Investor Relation & Corporate Communication
Dr. John W. Wallen III (Age 66)
VP of Intellectual Property, General Counsel & Secretary

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RNA Stock Analysis - Frequently Asked Questions

Should I buy or sell Avidity Biosciences stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avidity Biosciences in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RNA shares.
View RNA analyst ratings or view top-rated stocks.
What is Avidity Biosciences' stock price target for 2024?: 6 Wall Street research analysts have issued 1 year target prices for Avidity Biosciences' shares. Their RNA share price targets range from $20.00 to $60.00. On average, they predict the company's stock price to reach $36.33 in the next twelve months. This suggests a possible upside of 57.8% from the stock's current price.
View analysts price targets for RNA or view top-rated stocks among Wall Street analysts.
How have RNA shares performed in 2024?: Avidity Biosciences' stock was trading at $9.05 at the start of the year. Since then, RNA stock has increased by 154.5% and is now trading at $23.03.
View the best growth stocks for 2024 here.
When is Avidity Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RNA earnings forecast.
How were Avidity Biosciences' earnings last quarter?: Avidity Biosciences, Inc. (NASDAQ:RNA) released its quarterly earnings data on Wednesday, February, 28th. The biotechnology company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.25. The biotechnology company had revenue of $2.19 million for the quarter, compared to the consensus estimate of $32.08 million. Avidity Biosciences had a negative trailing twelve-month return on equity of 39.74% and a negative net margin of 2,219.87%.
What ETFs hold Avidity Biosciences' stock?: ETFs with the largest weight of Avidity Biosciences (NASDAQ:RNA) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON), Morningstar US Small Growth (MSGR), Simplify Propel Opportunities ETF (SURI), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and Harbor Disruptive Innovation ETF (INNO).iShares Micro-Cap ETF (IWC).

What other stocks do shareholders of Avidity Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Avidity Biosciences investors own include GTX (GTXI), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sarepta Therapeutics (SRPT), Avid Bioservices (CDMO), Dynavax Technologies (DVAX), iBio (IBIO), Intel (INTC), Ariad Pharmaceuticals (ARIA) and Corcept Therapeutics (CORT).
When did Avidity Biosciences IPO?: Avidity Biosciences (RNA) raised $150 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO.
Who are Avidity Biosciences' major shareholders?: Avidity Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.07%) and Mirador Capital Partners LP (0.06%). Insiders that own company stock include Arthur A Levin, Michael F Maclean, Rtw Investments, Lp, Sarah Boyce and W Michael Flanagan.
View institutional ownership trends.
How do I buy shares of Avidity Biosciences?: Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RNA) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial